Jonathan Chernoff (J Chernoff)

ResearcherID Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2015-2024
Publications (10 Years): 24

Top Venues

Oncogene

Science signaling

Research square

Molecular cancer research : MCR

Fox Chase Cancer Center

Mount School (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Fox Chase Cancer Center Sep 01 1991

United States

Scientific Director

Harvard University

United States

Postdoctoral Fellow :: Cellular and Developmental Biology

Beth Israel Medical Center

United States

Fellow :: Medical Oncology

Johns Hopkins School of Medicine

United States

Fellow :: Medical Oncology

University of Pittsburgh

United States

Intern/Resident :: Internal Medicine

Education History

Mount School

United States

PHD

Publications

Jonathan Chernoff, Konstantin Budagyan, Alexa Cannon, Adam Chatoff, Nathaniel W Snyder, Alison N Kurimchak, James Duncan
KRAS mutation-selective requirement for ACSS2 in colorectal adenoma formation. Research square (2024)
Alexa C Cannon, Konstantin Budagyan, Cristina Uribe-Alvarez, Alison N Kurimchak, Daniela Araiza-Olivera, Kathy Q Cai, Suraj Peri, Yan Zhou, James S Duncan, Jonathan Chernoff
Unique vulnerability of RAC1-mutant melanoma to combined inhibition of CDK9 and immune checkpoints. Oncogene 43 (10) (2024)
Alexa C Cannon, Konstantin Budagyan, Cristina Uribe-Alvarez, Alison N Kurimchak, Daniela Araiza-Olivera, Kathy Q Cai, Suraj Peri, Yan Zhou, James S Duncan, Jonathan Chernoff
Unique vulnerability of RAC1-mutant melanoma to combined inhibition of CDK9 and immune checkpoints. Oncogene 43 (10) (2024)
Daniela Araiza-Olivera, Tatiana Y Prudnikova, Cristina Uribe-Alvarez, Kathy Q Cai, Janusz Franco-Barraza, Jesús M Dones, Ronald T Raines, Jonathan Chernoff
Identifying and targeting key driver genes for collagen production within the 11q13/14 breast cancer amplicon. bioRxiv : the preprint server for biology (2024)
Alexa C Cannon, Konstantin Budagyan, Cristina Uribe-Alvarez, Alison N Kurimchak, Daniela Araiza-Olivera, Kathy Q Cai, Suraj Peri, Yan Zhou, James S Duncan, Jonathan Chernoff
Unique vulnerability of RAC1-mutant melanoma to combined inhibition of CDK9 and immune checkpoints. Oncogene (2024)
Jonathan Chernoff, Konstantin Budagyan, Alexa Cannon, Adam Chatoff, Nathaniel W Snyder, Alison N Kurimchak, James Duncan
KRAS mutation-selective requirement for ACSS2 in colorectal adenoma formation. Research square (2024)
Alexa C Cannon, Konstantin Budagyan, Cristina Uribe-Alvarez, Alison N Kurimchak, Daniela Araiza-Olivera, Kathy Q Cai, Suraj Peri, Yan Zhou, James S Duncan, Jonathan Chernoff
Unique vulnerability of RAC1-mutant melanoma to combined inhibition of CDK9 and immune checkpoints. Oncogene (2024)
Alexa C Cannon, Konstantin Budagyan, Cristina Uribe-Alvarez, Alison N Kurimchak, Daniela Araiza-Olivera, Kathy Q Cai, Suraj Peri, Yan Zhou, James S Duncan, Jonathan Chernoff
Unique vulnerability of RAC1-mutant melanoma to combined inhibition of CDK9 and immune checkpoints. Oncogene 43 (10) (2024)
Konstantin Budyagan, Alexa C Cannon, Adam Chatoff, Nathaniel W Snyder, Alison N Kurimchak, James S Duncan, Jonathan Chernoff
KRAS mutation-selective requirement for ACSS2 in colorectal adenoma formation. Research square (2024)
Alexa C Cannon, Konstantin Budagyan, Cristina Uribe-Alvarez, Alison N Kurimchak, Daniela Araiza-Olivera, Kathy Q Cai, Suraj Peri, Yan Zhou, James S Duncan, Jonathan Chernoff
Unique vulnerability of RAC1-mutant melanoma to combined inhibition of CDK9 and immune checkpoints. Oncogene 43 (10) (2024)
Alexa C Cannon, Konstantin Budagyan, Cristina Uribe-Alvarez, Alison N Kurimchak, Daniela Araiza-Olivera, Kathy Q Cai, Suraj Peri, Yan Zhou, James S Duncan, Jonathan Chernoff
Unique vulnerability of RAC1-mutant melanoma to combined inhibition of CDK9 and immune checkpoints. Oncogene 43 (10) (2024)
Olga Villamar-Cruz, Marco Antonio Loza-Mejía, Alonso Vivar-Sierra, Héctor Iván Saldívar-Cerón, Genaro Patiño López, Jonadab Efraín Olguín, Luis Ignacio Terrazas, Leonel Armas López, Federico Ávila-Moreno, Sayanti Saha, Jonathan Chernoff, Ignacio Camacho-Arroyo, Luis Enrique Arias-Romero
A PTP1B-Cdk3 Signaling Axis Promotes Cell Cycle Progression of Human Glioblastoma Cells through an Rb-E2F Dependent Pathway. Molecular and cellular biology (2023)
Dorothy Benton, Jonathan Chernoff
RHOA drivers take alternate routes in gastric cancer. Science signaling 16 (816) (2023)
Dorothy Benton, Jonathan Chernoff
RHOA drivers take alternate routes in gastric cancer. Science signaling 16 (816) (2023)
Dorothy Benton, Jonathan Chernoff
RHOA drivers take alternate routes in gastric cancer. Science signaling 16 (816) (2023)
Eleonora Sementino, Yuwaraj Kadariya, Mitchell Cheung, Craig W Menges, Yinfei Tan, Anna-Mariya Kukuyan, Ujjawal Shrestha, Sofiia Karchugina, Kathy Q Cai, Suraj Peri, James S Duncan, Jonathan Chernoff, Joseph R Testa
Inactivation of p21-Activated Kinase 2 (Pak2) Inhibits the Development of Nf2-Deficient Tumors by Restricting Downstream Hedgehog and Wnt Signaling. Molecular cancer research : MCR 20 (5) (2022)
Hoi-Yee Chow, Sofiia Karchugina, Brian J Groendyke, Sean Toenjes, John Hatcher, Katherine Aleisha Donovan, Eric S Fischer, Gleb Abalakov, Bulat Faezov, Roland L Dunbrack, Nathanael S Gray, Jonathan Chernoff
Development and Utility of a PAK1-Selective Degrader. Journal of medicinal chemistry 65 (23) (2022)
Cristina Uribe-Alvarez, Sandra Lucía Guerrero-Rodríguez, Jennifer Rhodes, Alexa Cannon, Jonathan Chernoff, Daniela Araiza-Olivera
Targeting effector pathways in RAC1P29S-driven malignant melanoma. Small GTPases 12 (4) (2020)
Alison N Kurimchak, Carlos Herrera-Montávez, Jennifer Brown, Katherine J Johnson, Valerie Sodi, Nishi Srivastava, Vikas Kumar, Safoora Deihimi, Shane O'Brien, Suraj Peri, Gina M Mantia-Smaldone, Angela Jain, Ryan M Winters, Kathy Q Cai, Jonathan Chernoff, Denise C Connolly, James S Duncan
Functional proteomics interrogation of the kinome identifies MRCKA as a therapeutic target in high-grade serous ovarian carcinoma. Science signaling 13 (619) (2020)
H Y Chow, B Dong, C A Valencia, C T Zeng, J N Koch, T Y Prudnikova, Jonathan Chernoff
Group I Paks are essential for epithelial- mesenchymal transition in an Apc-driven model of colorectal cancer. Nature communications 9 (1) (2018)
Maria Radu, Jonathan Chernoff
Recent advances in methods to assess the activity of the kinome. F1000Research 6 (2017)
D Araiza-Olivera, Y Feng, G Semenova, T Y Prudnikova, J Rhodes, Jonathan Chernoff
Suppression of RAC1-driven malignant melanoma by group A PAK inhibitors. Oncogene 37 (7) (2017)
Yi Zeng, Seongmin Hahn, Jessica Stokes, Emely A Hoffman, Monika Schmelz, Maria Proytcheva, Jonathan Chernoff, Emmanuel Katsanis
Pak2 regulates myeloid-derived suppressor cell development in mice. Blood advances 1 (22) (2017)
G Semenova, D S Stepanova, C Dubyk, E Handorf, S M Deyev, A J Lazar, Jonathan Chernoff
Targeting group I p21-activated kinases to control malignant peripheral nerve sheath tumor growth and metastasis. Oncogene 36 (38) (2017)
Rachelle E Kosoff, Joseph E Aslan, John C Kostyak, Essel Dulaimi, Hoi Yee Chow, Tatiana Y Prudnikova, Maria Radu, Satya P Kunapuli, Owen J T McCarty, Jonathan Chernoff
Pak2 restrains endomitosis during megakaryopoiesis and alters cytoskeleton organization. Blood 125 (19) (2015)

Jonathan Chernoff.css-eqlu8i{font-size:small;padding-left:4px;} (J Chernoff)

Publication Activity (10 Years)

Top Topics

Top Venues

Jonathan Chernoff (J Chernoff)